
Eli Lilly and Company LLY
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
897 M |
Market Cap[1] |
$ 1.14 T |
EBITDA (LTM) |
$ 2 B |
P/E (LTM) |
49.972174 |
P/S (LTM) |
15.822899 |
EPS (LTM) |
23.0 |
Eli Lilly and Company is one of the world's largest pharmaceutical companies, specializing in the development, manufacturing, and sale of innovative drugs for the treatment of various diseases.
The company was founded in 1876 in Indianapolis, Indiana and has since become a leader in the pharmaceutical industry. Eli Lilly and Company develops and manufactures a wide range of drugs, including those for diabetes, cancer, mental disorders, Alzheimer's disease, and other illnesses.
One of the company's most well-known developments is insulin, which was created in 1923. This drug became the first effective treatment for diabetes and has saved millions of lives worldwide.
Eli Lilly and Company actively invests in research and development of new drugs to help patients worldwide fight various diseases. The company also aims to improve the quality of life for patients by providing them with access to high-quality drugs. Is a global company with operations in more than 125 countries. The company cares about its employees and society as a whole, participating in various charitable projects and social responsibility programs.
Overall, is one of the most successful and innovative companies in the pharmaceutical industry. Its products help millions of people worldwide overcome difficulties associated with various diseases and improve their quality of life.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
ММЦБ
GEMA
|
- | - | - | MOEX | ||
|
Lyra Therapeutics
LYRA
|
- | - | $ 24.9 M | Nasdaq Global Market | ||
|
Завод ДИОД
DIOD
|
- | - | - | MOEX,SPB | ||
|
Фармсинтез
LIFE
|
- | - | - | MOEX | ||
|
ОЗОН Фармацевтика
OZPH
|
- | - | - | MOEX | ||
|
Промомед
PRMD
|
- | - | - | MOEX | ||
|
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | ||
|
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | ||
|
ESSA Pharma
EPIX
|
- | - | $ 8.86 M | Nasdaq Capital Market | ||
|
Generation Bio Co.
GBIO
|
- | - | $ 344 M | Nasdaq Global Select Market | ||
|
Clearside Biomedical
CLSD
|
- | - | $ 25.3 M | Nasdaq Global Market | ||
|
Merus N.V.
MRUS
|
- | - | $ 5.78 B | Nasdaq Global Select Market | ||
|
RAPT Therapeutics
RAPT
|
- | - | $ 2.36 B | Nasdaq Global Select Market | ||
|
Exicure
XCUR
|
$ 1.05 | -7.08 % | $ 6.61 M | Nasdaq Capital Market | ||
|
Cellectis S.A.
CLLS
|
$ 0.98 | 0.51 % | $ 98.3 M | Nasdaq Global Market | ||
|
AbCellera Biologics
ABCL
|
$ 11.82 | 3.96 % | $ 3.53 B | Nasdaq Global Select Market | ||
|
Arrowhead Pharmaceuticals
ARWR
|
$ 58.02 | -0.58 % | $ 7.76 B | Nasdaq Global Select Market,SPB | ||
|
BioMarin Pharmaceutical
BMRN
|
$ 55.95 | -1.2 % | $ 10.7 B | Nasdaq Global Select Market,SPB | ||
|
Celldex Therapeutics
CLDX
|
$ 29.25 | 0.97 % | $ 1.94 B | Nasdaq Global Select Market | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
$ 3.67 | 1.38 % | $ 44.8 M | Nasdaq Capital Market | ||
|
Jaguar Health
JAGX
|
$ 2.04 | -5.12 % | $ 4.76 M | Nasdaq Capital Market | ||
|
Protalix BioTherapeutics
PLX
|
$ 2.55 | -0.58 % | $ 200 M | NYSE American | ||
|
uniQure N.V.
QURE
|
$ 22.43 | -2.94 % | $ 1.29 B | Nasdaq Global Select Market | ||
|
Stoke Therapeutics
STOK
|
$ 25.04 | -2.57 % | $ 1.48 B | Nasdaq Global Select Market,SPB | ||
|
Xencor
XNCR
|
$ 25.18 | -2.55 % | $ 1.87 B | Nasdaq Global Select Market,SPB | ||
|
Annexon
ANNX
|
$ 3.75 | -1.57 % | $ 582 M | Nasdaq Global Select Market | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 1.78 | -2.73 % | $ 2.93 M | NYSE American | ||
|
Incyte Corporation
INCY
|
$ 115.71 | -1.04 % | $ 22.6 B | Nasdaq Global Select Market,SPB | ||
|
Mesoblast Limited
MESO
|
$ 12.28 | -2.15 % | $ 14.8 B | Nasdaq Global Select Market | ||
|
MeiraGTx Holdings plc
MGTX
|
$ 9.21 | -5.73 % | $ 741 M | Nasdaq Global Select Market | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
$ 523.93 | -2.1 % | $ 134 B | Nasdaq Global Select Market,SPB | ||
|
Abeona Therapeutics
ABEO
|
$ 4.4 | -1.57 % | $ 233 M | Nasdaq Capital Market | ||
|
AbbVie
ABBV
|
$ 285.64 | 0.24 % | $ 505 B | NYSE,SPB | ||
|
AIM ImmunoTech
AIM
|
$ 0.16 | -4.11 % | $ 259 K | NYSE American | ||
|
Akebia Therapeutics
AKBA
|
$ 0.57 | 0.84 % | $ 147 M | Nasdaq Global Market | ||
|
Arbutus Biopharma Corporation
ABUS
|
$ 4.2 | -0.24 % | $ 805 M | Nasdaq Global Select Market | ||
|
ACADIA Pharmaceuticals
ACAD
|
$ 19.73 | -2.86 % | $ 3.32 B | Nasdaq Global Select Market,SPB | ||
|
ADC Therapeutics SA
ADCT
|
$ 1.44 | -9.72 % | $ 183 M | NYSE | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
$ 25.51 | 4.51 % | $ 3.87 B | Nasdaq Global Select Market,SPB | ||
|
EyePoint Pharmaceuticals
EYPT
|
$ 0.4 | -5.51 % | $ 29.3 K | Nasdaq Global Market | ||
|
Seagen
SGEN
|
- | - | $ 42.2 B | Nasdaq Global Select Market,SPB | ||
|
Agios Pharmaceuticals
AGIO
|
$ 37.0 | -0.51 % | $ 2.14 B | Nasdaq Global Select Market,SPB | ||
|
Oncternal Therapeutics
ONCT
|
- | -24.12 % | $ 1.56 M | Nasdaq Capital Market | ||
|
Iterum Therapeutics
ITRM
|
- | - | $ 591 K | Nasdaq Global Select Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
Achieve Life Sciences
ACHV
|
$ 6.49 | -0.15 % | $ 283 M | Nasdaq Capital Market | ||
|
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | ||
|
Geron Corporation
GERN
|
$ 1.12 | -0.88 % | $ 747 M | Nasdaq Global Select Market | ||
|
Concert Pharmaceuticals
CNCE
|
- | - | $ 401 M | Nasdaq Global Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.